Description

Plasminogen activator inhibitor (PAI) influences the activation of plasminogen to plasmin, which in turn affects the rate of fibrinolysis. Plasma levels and genotype may influence a patient's risk of thrombosis or bleeding.


 

Forms of PAI:

(1) PAI type 1: usual form

(2) PAI type 2: usually not detectable; may be elevated in pregnant women

PAI Concentration

Effect on Fibrinolysis

Clinical Effect

increased

decreased

thrombosis

decreased

increased

bleeding

 

The plasma concentration of PAI is affected by:

(1) daily circadian rhythm (low in evening, high in morning)

(2) acute phase reaction to thrombosis (transiently increased)

(3) pregnancy (increased due to presence of PAI-2)

(4) genotype (increased with 4G allele, see below)

(5) presence of antifibrinolytic agents (if tested by functional assays)

(6) insulin resistance (increased levels)

 

The genotype of PAI affects the plasma level and the risk of thrombosis.

 

Genotype

Thrombosis Risk

5G/5G

none

4G/5G

minimal to mild

4G/4G

mild to moderate

 

The presence of either 4G/5G or 4G/4G genotype plus prothrombin G20210A was associated with increased risk of venous thrombosis (Barcellona et al).

 


To read more or access our algorithms and calculators, please log in or register.